OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease
Brian Bressler, Jennifer Jones, Tracy S. H. In, et al.
Advances in Therapy (2023) Vol. 40, Iss. 10, pp. 4421-4439
Closed Access | Times Cited: 6
Brian Bressler, Jennifer Jones, Tracy S. H. In, et al.
Advances in Therapy (2023) Vol. 40, Iss. 10, pp. 4421-4439
Closed Access | Times Cited: 6
Showing 6 citing articles:
Long‐term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study
María Chaparro, Sandra Hermida, Diana Acosta, et al.
Alimentary Pharmacology & Therapeutics (2024)
Open Access | Times Cited: 2
María Chaparro, Sandra Hermida, Diana Acosta, et al.
Alimentary Pharmacology & Therapeutics (2024)
Open Access | Times Cited: 2
Real-World Long-Term Persistence and Surgical Procedure-Free Period Among Bio-naïve Patients with Crohn’s Disease and Fistula Initiated on Ustekinumab
Maryia Zhdanava, Sumesh Kachroo, Porpong Boonmak, et al.
Advances in Therapy (2024) Vol. 41, Iss. 10, pp. 3922-3933
Closed Access | Times Cited: 1
Maryia Zhdanava, Sumesh Kachroo, Porpong Boonmak, et al.
Advances in Therapy (2024) Vol. 41, Iss. 10, pp. 3922-3933
Closed Access | Times Cited: 1
Low muscle mass is associated with efficacy of biologics in Crohn’s disease
Fang Ye, Luyan Fang, Mengqian Ye, et al.
Clinical Nutrition (2024) Vol. 43, Iss. 10, pp. 2354-2363
Closed Access | Times Cited: 1
Fang Ye, Luyan Fang, Mengqian Ye, et al.
Clinical Nutrition (2024) Vol. 43, Iss. 10, pp. 2354-2363
Closed Access | Times Cited: 1
Long‐term effectiveness and persistence rate of ustekinumab dose intensification in a South East Asian inflammatory bowel disease center
Chong Teik Lim, Shu‐Wen Tay, Sakktivel Elangovan, et al.
Journal of Gastroenterology and Hepatology (2024) Vol. 39, Iss. 8, pp. 1544-1553
Closed Access
Chong Teik Lim, Shu‐Wen Tay, Sakktivel Elangovan, et al.
Journal of Gastroenterology and Hepatology (2024) Vol. 39, Iss. 8, pp. 1544-1553
Closed Access
Real-World Treatment Persistence Among Advanced Therapy-Naïve or -Experienced Patients with Ulcerative Colitis Initiated on Ustekinumab or Adalimumab
Maryia Zhdanava, Sumesh Kachroo, Porpong Boonmak, et al.
Advances in Therapy (2024) Vol. 41, Iss. 10, pp. 3868-3887
Closed Access
Maryia Zhdanava, Sumesh Kachroo, Porpong Boonmak, et al.
Advances in Therapy (2024) Vol. 41, Iss. 10, pp. 3868-3887
Closed Access
Long-term efficacy and survival of ustekinumab therapy in patients with inflammatory bowel disease
М. В. Шапина
Meditsinskiy sovet = Medical Council (2024), Iss. 15, pp. 166-172
Open Access
М. В. Шапина
Meditsinskiy sovet = Medical Council (2024), Iss. 15, pp. 166-172
Open Access
